Inventor · disambiguated record
Sheri Moores
Also filed as: MOORES SHERI
14 granted patents·9 pending applications·92 citations·filing 2013–2024
91Inventor score
Top patents by PatentIndex Score
23 records- 0195US9593164B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2013·Granted Mar 14, 2017·34 cites·2 claims
- 0293US9580508B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2014·Granted Feb 28, 2017·19 cites·22 claims
- 0391US11459391B2Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Oct 4, 2022·7 cites·27 claims
- 0490US9695228B2EGFR and c-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2013·Granted Jul 4, 2017·15 cites·9 claims
- 0590US9695242B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2016·Granted Jul 4, 2017·8 cites·8 claims
- 0689US10662235B2Cysteine engineered fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted May 26, 2020·4 cites·15 claims
- 0783US9725497B2EGFR and C-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2013·Granted Aug 8, 2017·5 cites·13 claims
- 0882US12448455B2Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitorsJANSSEN BIOTECH INC·Filed 2023·Granted Oct 21, 2025·0 cites·23 claims
- 0976US12247077B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2021·Granted Mar 11, 2025·0 cites·26 claims
- 1076US2025236675A1Combination Therapies And Patient Stratification With Bispecific Ant-EGFR/C-MET AntibodiesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1175US2020087407A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2019·Application pending·0 cites
- 1274US12304939B2EGFR and C-met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2021·Granted May 20, 2025·0 cites·8 claims
- 1372US12215161B2Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2022·Granted Feb 4, 2025·0 cites·80 claims
- 1468US11879013B2Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitorsJANSSEN BIOTECH INC·Filed 2020·Granted Jan 23, 2024·0 cites·44 claims
- 1568US2018258173A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2018·Application pending·0 cites
- 1665US10954284B2EGFR and c-Met fibronectin type III domain binding moleculesJANSSEN BIOTECH INC·Filed 2017·Granted Mar 23, 2021·0 cites·6 claims
- 1762US2024067736A1Use of Anti-EGFR/Anti-Met Antibody to Treat Liver CancerJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1861US2017275367A1Bispecific EGFR/C-Met AntibodiesJANSSEN BIOTECH INC·Filed 2017·Application pending·0 cites
- 1960US2024228634A1Treatment of Cancers Lacking EGFR- Activating MutationsJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2058US2020325210A1Cysteine engineered fibronectin type iii domain binding moleculesJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 2153US2022298248A1Treatment of Cancers Lacking EGFR- Activating MutationsJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2251US12215160B2Treatment of patients having c-met exon 14 skipping mutationsJANSSEN BIOTECH INC·Filed 2021·Granted Feb 4, 2025·0 cites·47 claims
- 2335US2015087812A1Human Autotaxin Antibodies and Methods of UseCHI ELLEN·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sheri Moores files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →